KLRA is trading 4.5% down at $21.25 as investors continue to react to mixed Phase 3 results for its oral GLP-1 candidate.
- While the trial met primary endpoints, the market was disappointed by the candidate's weight-loss efficacy and reported gastrointestinal side effects.
- Today's decline appears to be a continuation of the sharp sell-off triggered on July 7, rather than a response to a new catalyst.
- Broader market weakness may be exacerbating the downward pressure, though the primary driver remains the company-specific clinical data.